Navigation Links
Trubion Presents Preclinical Data on Its SCORPION(TM) Multispecific Therapeutics at the 2009 American Association of Cancer Research Annual Meeting
Date:4/22/2009

SEATTLE, April 22 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) announced today presentation of preclinical data regarding its SCORPION(TM) multispecific therapeutic technology at the 100th Annual Meeting of the American Association of Cancer Research (AACR) in Denver. The data presented demonstrated the selectivity and high potency of the bispecific CD79BxDR SCORPION molecule, its differentiation from monospecific approaches, and its potential as a therapeutic for B-cell depletion, particularly in diseases refractory to CD20-targeted therapies.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090320/TRUBIONLOGO)

CD79BxDR SCORPION molecule: a single-chain, bispecific immunotherapeutic with potent in vitro activity against B-cell lymphoma

B-cell depletion with agents such as Rituxan(R) has proven successful in the treatment of hematological malignancies in the clinic, but patients still relapse and become refractory. Strategies to improve efficacy of B-cell directed therapies include boosting the cytotoxicity of agents and expanding to targets beyond CD20.

The objective of this preclinical model was to evaluate Trubion's SCORPION multispecific therapeutic as a next-generation candidate for oncology. An optimal bispecific molecule was identified that demonstrated highly potent activities against B-cell lymphoma cells in vitro.

The CD79BxDR SCORPION can bind to two different targets: CD79B, a lineage-restricted component of the B-cell antigen receptor, and HLA-DR, an HLA Class II molecule. Target binding by the SCORPION molecule has an affinity similar to Trubion's Small Modular Immunopharmaceutical (SMIP(TM)) proteins or monoclonal antibodies against th
'/>"/>

SOURCE Trubion Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related biology technology :

1. Trubion Pharmaceuticals, Inc. Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Systemic Lupus Erythematosus (SLE)
2. Trubion Pharmaceuticals Inc. Announces Work-Force Reductions and Restructuring
3. Trubion Announces Presentations at Upcoming Investor Conferences
4. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results
5. Trubion Announces Presentations at Upcoming Investor Conferences
6. Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis
7. Trubion Pharmaceuticals Wins Patent Opposition - Genentech / Biogen Idec European Patent Revoked
8. Trubion Pharmaceuticals to Present at Fall 2008 Morgan Stanley Global Healthcare Unplugged Conference in New York
9. Trubion Pharmaceuticals to Present at the 7th Annual Needham & Company Biotechnology & Medical Technology Conference
10. Trubion Announces Presentations at April/May Investor Conferences
11. Trubion Pharmaceuticals Inc. Reports Fourth-Quarter and Year-Ended 2007 Financial Results and Provides 2008 Financial Outlook

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)...OOMINGTON, Minn., Nov. 30 Acuo Tec...image management software, data migration tools an...a Hospitals and Clinics for a new Vendor Neutral A...orage across the Allina network of hospitals, clin...s based on the Acuo Technologies DICOM Services Gr...
(Date:11/30/2009)...OCKVILLE, Md., Nov. 30 N...cine company, announced today that the company wil...ference 2009 on December 2, 2009 at 12:30 pm local...ill provide an overview of the company,s business ...coming milestones. A link to the live audio only ...
(Date:11/30/2009)... AMSTERDAM, November 30 Biopharm...at the first patients have been enrolled in its,mu...TM). The study is,designed to show reduction in tr...llowing an allogeneic stem cell transplantation wi...ancer patients eligible for an allogeneic,stem cel...
(Date:11/30/2009)... CHANGCHUN, China and LOS ANGELES, Nov. 30 /PR...uticals, Inc. (OTC Bulletin Board: CYXN; ,China Yo...g manufacturer, distributor and,retailer of pharma...t has,completed preparation for distribution of me... Chinese government recently formalized the nation...
Breaking Biology Technology:Acuo Technologies Announces Contract for Vendor Neutral Archive With Allina Hospitals and Clinics 2Acuo Technologies Announces Contract for Vendor Neutral Archive With Allina Hospitals and Clinics 3NOVAVAX to Present at the Piper Jaffray 21st Annual Health Care Conference 2Kiadis Pharma Announces Enrollment of First Patients in a Multinational Registration Study for ATIR(TM) 2China Yongxin Pharmaceuticals Inc. to Distribute Medicines on the Essential Drug List 2China Yongxin Pharmaceuticals Inc. to Distribute Medicines on the Essential Drug List 3
...affiliate of,Phlo Corporation (Pink Sheets: PHLC) ...ion of its vitality product, AQUISS(TM), in Califo... within Northern California and has,been introduce...with the,Palm Desert/Palm Springs area. In Northe...ndiser,Holiday Meeting, which was instrumental in ...
...se Review with Drs. Morton Kern, Nico ...en and WILMINGTON, Mass., Oct. 19 The use,of frac...utcomes is the,topic of several sessions at this y...mposium, TCT 2007, which will take place Oct. 20-2...st company to develop systems that,calculate FFR w...
...PRNewswire-FirstCall/ -- Simcere,Pharmaceutical Gr...lier of,branded generic pharmaceuticals in the rap...hat it intends to release its 2007 third quarter r...ket opens in the United States.,Simcere,s chief ex...,officer, Frank Zhigang Zhao, will host an earning...
Other Biology Technology:AQUISS Continues Expansion Into New Territory 2Use of Fractional Flow for Optimizing Patient Outcomes is Topic of Several Sessions at TCT 2007 2Simcere Pharmaceutical Group to Announce Third Quarter 2007 Earnings on Monday, November 5, 2007 2Simcere Pharmaceutical Group to Announce Third Quarter 2007 Earnings on Monday, November 5, 2007 3
(Date:12/1/2009)...S, Ohio Ohio State University cancer researchers ...kills brain-tumor cells and blocks the growth of n...hat viruses designed to kill cancer cells oncolyt...sive brain tumors if they also carry a gene for a ...protein, called vasculostatin, is normally produce...
(Date:12/1/2009)..., NEW YORK, Dec. 1 iQor, a glob...services, was included in the 2009 InfoWorld 100...ic-enabled ERP system, TeQ21. This was the first s...cognized among this prestigious list of companies,...eQ21 is completely transforming the way we do busi...
(Date:12/1/2009)...ess, like a bad cold, can spread among groups of p...University of California-San Diego and Harvard sho...study that has been following health conditions fo...t lonely people tend to share their loneliness wit...disconnected people moves to the fringes of social...
Breaking Biology News(10 mins):Tumor-attacking virus strikes with 'one-two punch' 2iQor Named to InfoWorld 100 List of Top IT Projects of 2009 2Loneliness can be contagious 2Loneliness can be contagious 3Amilpar Operating Revenues Grew 9 25 in the Second Quarter and 11 25 in the First Half of 2009 54276 1Amilpar Operating Revenues Grew 9 25 in the Second Quarter and 11 25 in the First Half of 2009 54276 2Fenwal and Golden Meditech Agree to Form Joint Venture in China for Blood Collection and Transfusion Technologies 13513 1Fenwal and Golden Meditech Agree to Form Joint Venture in China for Blood Collection and Transfusion Technologies 13513 2Fenwal and Golden Meditech Agree to Form Joint Venture in China for Blood Collection and Transfusion Technologies 13513 3Postdiagnosis aspirin use reduces risk of dying from colorectal cancer 54274 1Postdiagnosis aspirin use reduces risk of dying from colorectal cancer 54274 2
...ity of North Carolina at Chapel Hill,s newest "lib...book lover, but it eventually will please thousand...ch researchers, work, it will undoubtedly contribu...t depend on every day, its developers say. , Named...oluminous genetic data on 39 plant species. The li...
... not for fun but for fuel. Burning grass for energ...r decades. But not in the United States. , Yet bur...rgy-efficient, environmentally friendly and sustai...t. , This alternative fuel easily could be produc...stoves built to burn wood pellets or corn, says Je...
...ns infectious disease specialists who have spent m... and AIDS worldwide are warning that limited inter...es currently being distributed in Africa, Asia and... afford to pay for them. , In an article appearing...une 28, infectious disease specialist Jonathan Zen...
Other Biology News:Unique library of plant genes germinates, takes root at UNC 2Grass makes environmentally friendly biofuel 2Hopkins AIDS experts issue warning about global efforts to provide drug therapies 2Hopkins AIDS experts issue warning about global efforts to provide drug therapies 3Hopkins AIDS experts issue warning about global efforts to provide drug therapies 4
Goat Anti-HIV-1 HIV1 p24 Antibody, Unconjugated from ABR-Affinity BioReagents
Anti-Human CD11b / Mac-1alpha Monoclonal Antibody, Unconjugated, Clone LM2 / 1 from Cell Sciences
RABBIT (BABY) COMPLEMENT LYOPHILISED from AbD Serotec
Rabbit Anti-Human ZO-1 Antibody, Unconjugated from Lab Vision
Biology Products: